Psychometric Properties of the Turkish Versions of the Cannabis Use Problems Identification Test (CUPIT) and the Adult Cannabis Problems Questionnaire (CPQ)


Evren C., Cengel H. Y. , Bozkurt M., Evren B., Umut G., Agachanli R.

JOURNAL OF PSYCHOACTIVE DRUGS, vol.49, no.1, pp.83-89, 2017 (SSCI) identifier

  • Publication Type: Article / Article
  • Volume: 49 Issue: 1
  • Publication Date: 2017
  • Doi Number: 10.1080/02791072.2016.1277047
  • Journal Name: JOURNAL OF PSYCHOACTIVE DRUGS
  • Journal Indexes: Social Sciences Citation Index (SSCI), Scopus
  • Page Numbers: pp.83-89
  • Keywords: Cannabis, CPQ, CUPIT, psychometric properties, synthetic cannabinoid, INVENTORY MSI-X, USE DISORDER, RELIABILITY, ALCOHOL, TRENDS, CONCURRENT, VALIDITY
  • Istanbul University Affiliated: Yes

Abstract

Cannabis and synthetic cannabinoids are widely used illicit substances in Turkey. The Cannabis Use Problems Identification Test (CUPIT) is a brief self-report screening instrument for detection of problematic cannabis use, whereas the Cannabis Problems Questionnaire (CPQ) is a measure for cannabis treatment outcome. The aim of this study was to evaluate the psychometric properties of the CUPIT and CPQ among Turkish male outpatients with cannabis (n = 52) and synthetic cannabinoid (n = 45) use disorder. Participants were evaluated with the CUPIT, the CPQ, and the Cannabis Withdrawal Scale (CWS). Principal Component Analysis (PCA) supported two-factor construct validity for CUPIT. Cronbach's alpha was 0.84 for CUPIT-A factor, 0.83 for CUPIT-B factor, and 0.89 for CUPIT, when considered as a unidimensional scale. Cronbach's alpha was 0.82 for CPQ-A factor, 0.73 for CPQ-B factor, 0.30 for CPQ-C, and 0.87 for CPQ, when considered as a unidimensional scale. The CUPIT and the CPQ were moderately correlated with the CWS (r = 0.63 and r = 0.74, respectively), whereas the CUPIT and the CPQ were strongly correlated with each other (r = 0.76). The Turkish version of the CUPIT and the CPQ can effectively identify substance use problems and treatment outcome, respectively, among outpatients with cannabis or synthetic cannabinoid use disorder.